ZyVersa Therapeutics, Inc.

OTC: ZVSA · Healthcare · Biotechnology

PublicHQ Weston, FL · BrowardCIK 0001859007Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 9DQ —GM —SS 21

v0.1 · 35/100 weight · pillars only

↑ filing timeliness, market scale · ↓ Piotroski F, return on assets

Methodology →

Revenue TTM

Rev growth YoY (TTM)

-100.0%

Net income (FY)

-$25.0M

Employees

as of 2026-08-26

Market cap

$805.5k

as of 2026-08-26

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$25.0M-$25.0M2025

Operating income-$25.5M-$25.5M2025

Total assets$347.9k$347.9k2025

Liabilities$12.7M$12.7M2025

Equity-$12.4M-$12.4M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is ZyVersa Therapeutics, Inc.’s financial profile?

ZyVersa Therapeutics, Inc. earned -$25.0M in FY2025 net income.

Peers · Healthcare

Suvanza Pharma, LLC——Lakewood-Amedex Biotherapeutics Inc. Common Stock——RushNet, Inc.——XORTX Therapeutics Inc.——China Health Management Corp.——Nascent Pharma Holdings, Inc.——

Neighbors

Broward →

HEICO Corporation$4.5B84B+Chewy, Inc.$12.6B58C Element Solutions Inc$2.6B78B+AutoNation, Inc.$27.6B74B VSE Corporation$1.1B69B Willis Lease Finance Corporation$730.2M72B

Key facts

CEOStephen C. Glover

SectorHealthcare

IndustryBiotechnology

HeadquartersWeston, FL

ExchangeOTC: ZVSA

Employees6

IPO date2022-02-11

Latest filings

8-K2026-07-16 8-K2026-07-10 10-Q2026-05-13 10-K2026-03-31 8-K2026-03-05 8-K2025-12-03 10-Q2025-11-19 8-K2025-11-19

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.